Eclipse Bioinnovations Inc. (Eclipsebio), a provider of sequencing-based analytics for RNA therapeutics, has acquired Terrain Bio, a techbio company specializing in AI/ML RNA design and manufacturing analytics.

According to Peter Chu, CEO of Eclipsebio, “This acquisition meaningfully advances our vision for Eclipsebio.” He says, “Terrain Bio’s proven AI design capabilities strongly complement our sequencing-first analytics, allowing us to support RNA drug developers earlier in development while continuing to deliver the deep sequencing-based validation our partners rely on for confident decision-making.”

Terrain Bio has developed advanced machine learning models for RNA sequence optimization and active learning workflows, alongside an R&D-scale mRNA manufacturing platform, to connect computational design directly with experimental feedback. By integrating these capabilities with Eclipsebio’s established sequencing-based datasets and quality control platforms, including eMERGE and eVERSE, Eclipsebio will offer partners a unified Design, Make, Test solution that continuously improves as new data are generated in the development of RNA-based medicines.

The combined platform will enable RNA therapeutic developers to:

• Iteratively design optimized RNA constructs using AI modeling and active learning;
• Measure structure, translation, and impurities with high-resolution sequencing analytics; and
• Gain actionable insight into manufacturing robustness and quality-by-design.

“Eclipsebio’s deep expertise in sequencing-based validation and curated data repository makes this combination uniquely powerful,” said Chetan Tadvalkar, CEO of Terrain Bio. “Together, we close the gap between computational design and real-world experimental validation, helping RNA therapeutics reach the clinic faster and with greater confidence.”

Eclipsebio will continue to support existing Terrain Bio customers and will work closely with its partners to ensure a seamless transition.

Other Pharma Industry Acquisitions

Check out Contract Pharma’s Pharmaceutical Industry Mergers & Acquisitions Roundup.